In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
HOME > ACADEMIA
ACADEMIA
- Japan Hematology Society to Open Probe into SIGN Trial
March 19, 2014
- Lead Author to Revise COI Statement in Article Used to Promote Antidepressant Cymbalta
March 19, 2014
- Trial Investigators Brush Aside Concerns over CASE-J in US Journal
March 18, 2014
- JSH Guidelines to Strongly Recommend Beta Blockers for Patients with Certain Complications
March 18, 2014
- University of Tokyo Admits Patient Information on SIGN Trial Leaked to Novartis
March 17, 2014
- National University Hospitals to Disclose Funding from Autumn, but with Company Names Withheld
March 11, 2014
- JAMS’s Newly Revised COI Management Guidelines Impose Stricter Rules
February 28, 2014
- Japanese Cardiologist Raises Statistical Concerns over CASE-J Study in US Journal
February 28, 2014
- NCNP to Begin Investigator-Initiated Trial of Multiple Sclerosis Treatment
February 28, 2014
- Japan Diabetes Society Crosses Out SMART Study from Its Guidelines
February 25, 2014
- US Journal Officially Announces Retraction of SMART Study
February 24, 2014
- Japan Hypertension Society Halts Support for Maker-Linked Seminars, but Gives Leeway for Luncheons
February 18, 2014
- University of Tokyo Hospital Allegedly Gave Patient Questionnaire Results on SIGN Trial to Novartis without Consent
February 13, 2014
- SMART Study Sub-Analysis Paper to Be Retracted from JSH Journal
February 12, 2014
- University of Tokyo Besieged with Medical, Pharma Research Woes, School’s Credibility at Stake
February 7, 2014
- JAS Sees “No Need” to Change Its Guidelines in Response to 2013 ACC/AHA Guidelines for the Prevention of ASCVD
February 5, 2014
- SGLT-2 Inhibitors “Suited to Patients with Tendency to Obesity”: Prof. Kadowaki of Univ. of Tokyo
February 4, 2014
- Japan Hypertension Society Won’t Co-Sponsor or Support Drug Maker-Linked Seminars for Now
January 29, 2014
- JCS’s 2013 Guidelines for Treatment of AF Recommend Dabigatran and Apixaban in Moderate-Risk Patients
January 29, 2014
- SMART Study Should Be Removed from CKD Guidelines: Society Panel Chair
January 22, 2014
ページ
An increasing number of companies in Japan are showing an eagerness to snatch up “drug loss” assets. As of this…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…